TY - JOUR
T1 - Towards harmonization of clinical tools for assessing Brain Involvement in Dystrophinopathies (BIND); report of four expert workshops
T2 - Newcastle, Leiden, Rome, Paris
AU - Hendriksen, Jos
AU - Weerkamp, Pien
AU - Miranda, Ruben
AU - Kolesnik, Anna
AU - Chieffo, Daniela
AU - Skuse, David
AU - Vroom, Elizabeth
AU - Geagan, Chloe
AU - Muntoni, Francesco
AU - Mercuri, Eugenio
AU - BIND WP5 working group
PY - 2024/10/4
Y1 - 2024/10/4
N2 - As part of an international project aimed at improving the characterization of brain involvement in Duchenne and Becker Muscular Dystrophies, a group of clinicians, researchers and family associations held multiple meetings between March 2021 and March 2024 to identify and reach a consensus on the possible tools that could assess the spectrum of neurocognitive and neurobehavioral brain comorbidities in dystrophinopathies. Consensus was achieved on which of these tools should be used across different settings, ranging from screening to clinical practice and scientific research. Screening questionnaires were found to be valuable not only for providing epidemiological data but also for raising awareness among the Duchenne community and professionals. More standardised and detailed online questionnaires, combined with in-depth clinical assessments can help better identify the profile of brain comorbidities and plan appropriate interventions. Additionally, the information gathered from assessing multiple features of brain involvement can be used to explore correlations with other aspects, such as the regional expression of the different dystrophin isoforms, brain imaging, and the animal models deficient in these isoforms.
AB - As part of an international project aimed at improving the characterization of brain involvement in Duchenne and Becker Muscular Dystrophies, a group of clinicians, researchers and family associations held multiple meetings between March 2021 and March 2024 to identify and reach a consensus on the possible tools that could assess the spectrum of neurocognitive and neurobehavioral brain comorbidities in dystrophinopathies. Consensus was achieved on which of these tools should be used across different settings, ranging from screening to clinical practice and scientific research. Screening questionnaires were found to be valuable not only for providing epidemiological data but also for raising awareness among the Duchenne community and professionals. More standardised and detailed online questionnaires, combined with in-depth clinical assessments can help better identify the profile of brain comorbidities and plan appropriate interventions. Additionally, the information gathered from assessing multiple features of brain involvement can be used to explore correlations with other aspects, such as the regional expression of the different dystrophin isoforms, brain imaging, and the animal models deficient in these isoforms.
U2 - 10.1016/j.nmd.2024.104452
DO - 10.1016/j.nmd.2024.104452
M3 - Article
SN - 0960-8966
VL - 44
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
M1 - 104452
ER -